RxDoctor Payments Data

David Morris, MD

Cardiovascular Disease · Las Vegas, NVNPI 1427361534

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $9,035 of the $13,765 with a category attached, or 65.6%. 19 manufacturers reported payments, led by Boehringer Ingelheim at 57.9% of the total. Reporting peaked in 2022 at $10,412 and has fallen 98.7% since, to $139 in 2025.

$13,765in general payments, 2019–2025

Across 109 payments — averaging $126.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$8K
  • Lilly USA, LLC$2K
  • Amgen$819
  • Novartis$584
  • Johnson & Johnson$478
  • Abiomed$337
  • plus $2K from 13 others

What the payments were for

  • Consulting fees$2752%
  • Speaking & faculty fees$9,03566%
  • Travel & lodging$300%
  • Food & beverage$3,42525%
  • Education$9997%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,765 in reported general payments places this provider in the 80th percentile of 165 cardiovascular disease providers in Nevada.

See all cardiovascular disease providers in Nevada

Medicare billing

Part B allowed, 2024
$37,543
Medicare patients
163
Services billed
392

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban481$545,508
EntrestoSacubitril/Valsartan174$223,543
XareltoRivaroxaban159$177,146
JardianceEmpagliflozin85$119,247
Repatha SureclickEvolocumab43$26,385
BrilintaTicagrelor15$11,392
Praluent PenAlirocumab20$10,986
Atorvastatin Calcium694$6,073
Ranolazine ErRanolazine25$3,839
Metoprolol Succinate347$3,480
Metoprolol Tartrate266$1,947
Carvedilol221$1,829
Rosuvastatin Calcium193$1,791
Amlodipine Besylate196$1,745
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide169$1,658

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$545,508481 claims
NovartisEntresto$584$223,543174 claims
Johnson & JohnsonXarelto$478$177,146159 claims
Boehringer IngelheimJardiance$7,965$119,24785 claims
AstraZenecaBrilinta$120$11,39215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 165 cardiovascular disease providers in Nevada.

Other cardiovascular disease in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →